Mounjaro becomes available on the NHS: what to know and what to do if you're not eligible
Obesity remains one of the most pressing, and preventable, health challenges of our time. The UK is one of a number of countries undoubtedly struggling with it.
It affects nearly every organ system in the body, contributing to cardiovascular conditions like coronary heart disease; musculoskeletal issues such as osteoarthritis and gout; and even the development of certain cancers, including of the breast, uterus and colon. Its impact on mental health is also significant.
A few years ago, injectable weight-loss drugs entered clinical use and quickly captured public attention for their ability to promote rapid fat loss. Ozempic is available on the NHS, but only for managing type 2 diabetes. Wegovy is authorised for weight loss and cardiovascular risk reduction and is also available on the NHS, though access is currently limited to specialist weight management services.
Now, a new option has emerged: Mounjaro, which is approved for both type 2 diabetes and weight loss. This dual-purpose drug is now available on the NHS, offering another potential tool in the fight against obesity.
Demand is expected to be high. However, access will be limited at first, with strict eligibility criteria for NHS prescriptions.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Mounjaro (tirzepatide) is a once weekly injectable medication designed to help control blood-sugar levels. It works by boosting the secretion and effects of insulin, improving glycaemic control in people with Type 2 diabetes. It also slows gastric emptying — the process by which food leaves the stomach — and enhances feelings of fullness by acting on the brain. This combined effect reduces appetite and helps support weight loss.
Compared to similar medications like Ozempic and Wegovy (both brand names for semaglutide), clinical trials found Mounjaro more effective, with some participants losing up to 20% of their body weight over a 72-week period.
Read more:
The NHS has introduced specific criteria to prioritise patients most in need.
First, patients need a BMI of 40 or more (classified as morbid obesity). People from certain ethnic backgrounds, such as South Asian communities, may be eligible at a lower BMI due to higher clinical risk of health conditions.
Second, at least four obesity-related health conditions must be diagnosed, including type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglyceride levels), cardiovascular disease and obstructive sleep apnoea. (Some of these conditions often occur together; for example, high blood pressure and cholesterol.)
Patients are encouraged to check their BMI and confirm their diagnoses before contacting a GP. This helps ensure appointments are used effectively and discussions remain focused.
While the current criteria are strict, there is optimism that eligibility will broaden in the coming years to include people with lower BMIs and fewer co-morbidities.
The NHS continues to offer a comprehensive weight-loss programme, tiered according to BMI and previous attempts at weight loss. Don't underestimate the value of group-based programmes or community referrals – when a healthcare professional refers a patient to a community-based health service for further care or support – many of which can be accessed via your GP.
These services, such as the NHS digital weight management programme, support both individuals and families and can be highly effective for sustainable fat loss.
GPs may also refer patients to online courses and structured exercise programmes. Lifestyle interventions, including increased physical activity and healthier eating, remain cornerstones of obesity treatment and are critical for long-term success, even when medications are used.
Read more:
Higher tier interventions may be considered if lifestyle changes fail or if the patient has significant co-morbidities. This is where medications like Mounjaro, or private prescriptions, may become relevant – albeit that the cost of the latter may be a limiting factor for some.
Other treatments include Orlistat, a medication that reduces fat absorption in the gut. This can be effective for some but often causes unpleasant side effects, such as oily stools and gastrointestinal upset
Gastric banding or surgery may also result in significant, sustained weight loss, but they come with risks, can lead to surgical complications, and recovery can be demanding
It's also important to recognise that drugs like Mounjaro aren't suitable for everyone. They can cause side effects significant enough for people to stop using them, and in some cases, they may not work at all.
In this new era of faster, medication-assisted weight loss, we must remember that long-term change is about more than quick fixes. Sustainable success comes from consistent effort, willingness to change and methods that are both practical and lasting.
Medications can help, sometimes dramatically, but they're not the only answer. A return to basics, with tailored support and realistic goals, remains as relevant as ever.
So whether you qualify for Mounjaro, are trying lifestyle changes, or are exploring other options, remember this: the journey to better health is personal, gradual and worth it.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Experimental drug helps patients lose nearly a quarter of body weight in early trials
Print Close By Melissa Rudy Published June 23, 2025 An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion. "Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule," Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital. GRANDFATHER'S SIMPLE CHANGES REVERSED PRE-DIABETES DIAGNOSIS THAT LEFT HIM 'PETRIFIED' In the study, which included 125 overweight or obese adults, participants who received weekly injections of amycretin lost more weight than those who took a placebo, according to a press release from Novo Nordisk. Those who got the highest doses (up to 60 mg) lost up to 24.3% pounds after 36 weeks, compared to just 1.1% for the placebo group, per the release. A previous phase 1 trial of the oral (pill) version of amycretin also showed that treatment was "safe and tolerable," with an "observed reduction in body weight" compared to placebo, the company stated. Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%. YOUR DNA COULD BE STOPPING YOU FROM LOSING WEIGHT, NEW STUDY SUGGESTS Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a "weight-loss plateau," continuing to shed pounds as long as they took it. "The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment," Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the phase 1 study findings. Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22; they were also published in the medical journal Lancet. "We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management," said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in the release. "Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule." "These results reflect our robust pipeline in obesity, [and] our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals." The most common side effects of amycretin, similar to other GLP-1s, were gastrointestinal symptoms — primarily nausea, vomiting and decreased appetite. CLICK HERE TO GET THE FOX NEWS APP Adverse events were "mild to moderate" in severity, according to researchers. More frequent doses resulted in greater side effects. It's important to monitor these side effects closely, experts advise, as GI issues are common among patients with obesity. "While the initial weight-loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration," Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, previously told Fox News Digital. CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER While GLP-1-based drugs — including this new experimental pill — may show promising results, Ren-Fielding, who was not involved in the study, emphasized that they're "not a cure-all for obesity." "Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach," she said at the time. For more Health articles, visit "Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions." Next, Novo Nordisk plans to prepare for phase 3 trials of the medication, in both oral and injectable forms, for the management of obesity. Print Close URL
Yahoo
2 hours ago
- Yahoo
Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the popular weight-loss drug, Wegovy. The Danish pharmaceutical giant and Hims & Hers had initially partnered in April, with plans for the telehealth company to offer Wegovy as part of a bundled package on its platform. Despite the halt, Hims & Hers stated earlier this month that it intends to continue selling "personalised" doses of Wegovy, priced from approximately $165 a month. This approach, according to Hims, is permissible under clinical guidelines, citing reasons such as reduced side effects. Hims also provides liraglutide, a generic version of an older Novo Nordisk diabetes medication known for its weight-loss effects, alongside branded Wegovy and Eli Lilly's competing drug, Zepbound. Wall Street analysts have questioned whether Hims' offerings actually qualify as "personalized" and say it is unclear if Novo, which has said mass production of copies is breaking the law, will allow it. Hims & Hers was not immediately available for a comment outside of the company's regular work hours. A U.S. federal judge on Friday rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's decision to remove the drugs' active ingredient, semaglutide, from the shortage list. "Efforts will continue to make authentic, FDA-approved Wegovy directly available through NovoCare Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients," Novo said. Novo's share price fell following the announcement, extending an earlier decline to trade down 6.5% by 1315 GMT. Shares of Hims and Hers fell 22% to $50.02 in U.S. premarket hours.
Yahoo
2 hours ago
- Yahoo
Hims & Hers, healthcare stocks, BNY: Trending Tickers
Novo Nordisk (NVO) ended its weight-loss drug partnership with Hims & Hers (HIMS), sending shares of both companies lower. UnitedHealth (UNH), CVS (CVS), and Cigna (CI) are in focus as health insurers are set to simplify the authorization process, according to AHIP. BNY Mellon (BK) is reportedly considering a merger with Northern Trust (NTRS), according to the Wall Street Journal. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Time now for some of today's trending tickers. We are watching Novo Nordisk, Hims and Hers, Health Insurers, and Bank of New York Melon. First up, Hims and Hers shares plunging after Novo Nordisk says it's ending its partnership with the company that allowed the direct sale of its Wegovy. The pharmaceutical company saying Hims and Hers allegedly failed to follow laws prohibiting mass sales of compounded drugs and accusing the company of deceptive marketing that put patient safety at risk. There you're taking a look at the share price reaction here for both of the companies here. And it's notable because as what we had seen with Hims and Hers, it was certainly an effort by them to ensure that they could have some type of weigh-in on the user demand that they have seen flow into their different products where they had largely looked across some of the patents that expired and knew that they had to be in on the weight loss drug trend as well. And so partnership with Novo Nordisk was significant, but now it also means that you have to comply with some of the service-level agreements or expectations that that company you're partnering with has too. Yeah, it's been a tough ride for Hims and Her shareholders. I mean, the volatility in that stock has been epic, and it goes from one drug to the next, whether it's ED medication or now weight loss drugs. Uh, they have, you know, so much promise, such a great, loyal user base. It's a fantastic alternative, uh, for people, you know, it's secretive, it's online, it's right your door. Uh, so when this news happened, maybe it was a little bit of an overreaction, but, uh, to see it fall over 20% last I checked, uh, uh, extreme. And, uh, so we have to see what the next step is for them, but this was a big blow to their shareholders, and we'll see how they recover from that. Yeah, shareholders who've watched the stock actually move higher even with today's move, it seems, move higher year to date, 82%, but this major pullback certainly is going to test some of the mindset around the investment thesis for Hims and Hers. We're going to be continuing to watch that. We're also watching major health insurers signal a move towards simplifying prior authorization requirements for medicines and services. So, America's health insurance plans, an industry organization for insurers, they say that insurance companies will develop standard data and submission requirements by January 1st, 2027. Additionally, major insurers will cut down on claims that require prior authorization by January 1st, 2026 and will make sure authorizations are valid for 90 days if a patient chooses to change insurers during the treatment here. You're seeing shares kind of move in different directions for United Health, which has been facing its own problems over the course of the year. Uh, but then two of the other insurers that we were showing on screen still moving higher here. And the insurance space is undergoing a vast majority of targeted changes, whether that be in how the claims are adjusted and looked through and evaluated, all the way through to the pricing and how the different models in their pricing are carried out as well here. So, a spate of changes that could be coming over the course of this year, which has have given investors a lot to think about with these insurers. Yeah, it's been the one sector in trouble times that usually does well, and it's been the second worst performing sector year to date. Only discretionary lags, and it's one of two that are down. Uh, we know UNH has had their own troubles. That goes without saying. But the sector itself has been beaten down. Anything that can one help us as, you know, users of these platforms, streamline operations, cut costs down. Oh, yeah. I mean, it's ridiculous. But this is something the Trump administration had talked about for a while. Uh, we just have yet to see some results, and this may not bode well for the insurers themselves, but for the utilizers of those insurances, any anything to streamline operations would be great. So, I don't see an uptake in the sector as a result of something like this, but it's positive progress, at least for, you know, you and I. Absolutely. And finally here in our trending tickers, we're continuing to track Bank of New York Melon eyeing a potential merger with Northern Trust. This is according to the Wall Street Journal here. Now, the chief executives of Bank of New York Melon and Northern Trust reportedly had at least one conversation, and BNY is considering next steps. BNY had no comment on the report here. A merger between the two companies would create an investment management giant overseeing more than 3 trillion dollars in assets. There you're taking a look at both of these firms. And the larger question upon the industry and the sector at large for banking and financial services is what this means for broader consolidation efforts right now to shore up some of their own operations. We have been waiting for a story like this to happen for ages. I'm talking 15, 20 years, pre-financial crisis. We've had bank mergers, but what have they been a result of? They've been a result of failures, uh, results of insolvency from some of these smaller banks. We had the regional banking crisis. So for this to start, this is something that we had predicted would happen under the Trump administration, lack of red tape, a lot of regional bank M&A activity. I look at some of these bigger regional banks, the PNCs, the M&Ts, the Regions Financials of the world. Technically, they've broken down trends, and they're looking like they want to reverse. You look at this Northern Trust. Okay, uh, it's trading around 120, 122. I didn't see the last sale. Uh, but its high was January 13th, 2022, of 133, 135 in that range. So if this deal is going to get done, and there's a little smoke usually in these things do get higher and out, I think there's an upside to at least that level to get the deal across the finish line, and the stock has been doing well. So this, to me, is fantastic. And when you have Bank of New York, Bank of New York Melon, first stock to ever trade the New York Stock Exchange, fun fact, BNY. Uh, Alexander Hamilton, he's not involved in this deal, but uh, this is something that investors should be happy about. If you look at the KRE, which is the regional bank sector, very wide swath of them underperforming the BKX, which is, you know, includes some regional, some of the larger banks. Uh, this is something that you may want to take a flyer on because this goes through, this happens, there are going to be a lot of other people having conversations over the few, uh, upcoming months. It's interesting, and it brings me back to one of the thought processes that we had heard from Torsten Slok of Apollo, the chief economist there, who had put out within his banking sector outlook. Banking sector balance sheets are generally in good shape, credit growth positive driven by lending in large banks, but it does make you consider how many of these banks are trying to make sure that they're diversifying their streams of revenue and their income here, and what could be possibly pushing this deal forward is that thought process from these two major entities. Without a doubt, and this would put Bank of New York into the Chicago market. You know, they have Pittsburgh with Melon, but, uh, to me, yes, uh, rates have been stable and steady, higher for longer. They've absorbed this, all the banks have. Uh, mortgage market has been kind of tricky. So maybe it's the time for some of these smaller banks to find a larger partner. And you get some of these super regionals joining forces. To me, it makes sense, and we have the administration to back it. So, uh, I think this is something to really keep a close eye on going forward. Yeah, to your point, potentially larger footprint that we could be seeing here if this goes through. You could scan the QR code below to track the best and worst performing stocks of this session with Yahoo Finance's trending tickers page.
